1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
"Efficient and Innovative Natural History Studies Addressing Unmet Needs in Rare Diseases (R01 Clinical Trials Optional)" is currently closed and not accepting applications.
Efficient and Innovative Natural History Studies Addressing Unmet Needs in Rare Diseases (R01 Clinical Trials Optional) is sponsored by FDA Office of Orphan Products Development (OOPD). This funding opportunity supports efficient and innovative natural history studies that advance medical product development in rare diseases/conditions with unmet needs.
The goal is to address critical knowledge gaps, remove major barriers to progress, and facilitate rare disease product development through high-quality and interpretable data.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Not explicitly stated in the search results, but typically targets academic institutions, research organizations, and pharmaceutical companies capable of conducting natural history studies. Confirm the full requirements in the official notice before applying.
The published deadline was February 10, 2026, which has passed. Check the official notice for any future application windows before investing time in a proposal.
Efficient and Innovative Natural History Studies Addressing Unmet Needs in Rare Diseases (R01 Clinical Trials Optional) is funded by FDA Office of Orphan Products Development (OOPD). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
The BARK program funds dual-use medical products for warfighters and military working dogs — tourniquets, sensors, drug delivery, and CBRN countermeasures. Proposals close June 3, 2026.
Read articleARPA-H is funding the first agentic AI system that can prescribe medications, monitor patients 24/7, and manage heart disease autonomously. Here is what applicants need to know.
Read article